Compositions for nucleic acid delivery

ABSTRACT

The invention provides compositions containing at least one ligand such as human epidermal growth factor (EGF) or human vascular endothelial growth factor (VEGF), a nucleic acid and a human transferrin ligand. The compositions are useful for the multi-targeted delivery of nucleic acids to cells and tissues.

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] The instant application is related to application Ser. Nos. ______; ______; ______; ______; ______; ______; ______; ______; ______; ______ and ______; all filed on even date herewith under Express Mail labels EV 140261687 US; EV 140261673 US; EV 140261660 US; EV 140261585 US; EV 140261571 US; EV 140261568 US; EV 140261554 US; EV 140261537 US; EV 140261523 US; EV 001630855 US and EV 001630847 US; the contents of which are each herein incorporated by reference.

FIELD OF THE INVENTION

[0002] The instant invention relates generally to compositions useful for the delivery of nucleic acids to cells and tissues; particularly to compositions useful for multi-targeted delivery of nucleic acids to cells and tissues and most particularly to compositions containing at least one ligand such as human epidermal growth factor (EGF) or human vascular endothelial growth factor (VEGF) and at least one nucleic acid each operatively linked to a human transferrin ligand useful for multi-targeted delivery of nucleic acids to cells and tissues.

BACKGROUND OF THE INVENTION

[0003] The possibility of delivering foreign or heterologous genetic material into cells raises hope for the development of many new therapeutics. Prior artisans have produced compositions and methods useful for both in vitro and in vivo delivery of nucleic acids.

[0004] In order for efficient uptake of nucleic acid to occur, the nucleic acid must have direct contact with the cells to which it is to be delivered. Cells in vitro are easily physically accessible to direct contact through methods such as co-precipitation with calcium phosphate, electroporation, microinjection and particle bombardment (“gene gun”; firing of metallic microprojectiles coated with nucleic acid at the target cells). Cells in vivo are often not easily physically accessible to the direct contact necessary for efficient uptake of nucleic acids. Thus, although the above-referenced techniques are effective for in vitro use, they are impractical and potentially damaging for use in vivo.

[0005] Nucleic acids to be delivered to target cells in vivo, are usually transported through the circulatory system where they are subject to damage and clearance from the body before ever reaching their target cells. Thus, carriers are employed for transport of nucleic acids in vivo in order to provide protection from damage and to prolong half-life. The efficiency of transport directly influences the resulting level of gene expression, meaning, for example, if transport is efficient, the uptake of nucleic acid is increased followed by an increase in gene expression. The ideal approach involves injection of nucleic acid complexed with a carrier into the circulation of a host followed by the “homing in” of the nucleic-acid carrier complex on the appropriate target cell to exclusion of all other cell types. However, to date, since most delivery methods lack selectivity, this “homing in” or targeting of nucleic acids to specific cells in vivo has proven to be an elusive goal for researchers. This difficulty of targeting nucleic acids to specific cells at the exclusion of all other cell types is a major barrier to progress in the development of effective in vivo delivery techniques. There are several broad categories of compositions and methods currently employed for in vivo delivery including; nucleic acid condensing agents, polymer systems, liposomes, viral vectors, and peptide-enhanced delivery methods.

[0006] For successful in vivo application it is important that nucleic acid delivery carriers be small enough to gain access to target cells by passage through cellular membranes. DNA can be condensed into small polyelectrolyte complexes by the addition of polycations, such as poly (L) lysine. These small complexes facilitate the transfer of DNA across the cell membrane for delivery to the nucleus. These polyelectrolyte complexes have shown limited usefulness due to rapid clearance from the circulation following intravenous injection. This rapid clearance results from destabilization of the polyelectrolyte complexes by serum proteins and degradation of the polyelectrolyte complexes by serum proteases.

[0007] Polymer systems have also been used for the delivery of nucleic acids, for example, by complexing nucleic acid with silica or by complexing nucleic acid with polymeric cations such as natural proteins and starches. However, these systems are lacking in selectivity and are subject to degradation and rapid clearance from the body.

[0008] Liposomes are phospholipid bilayer vesicles that can be used to encapsulate and transport nucleic acids. The nucleic acid is trapped in the aqueous compartment of the liposome and enclosed by the completely sealed lipid bilayer. The membranes of most cells have a net negative charge and thus the cationic nature of liposomes allows for attraction of the liposome to the cellular membrane resulting in fusion of the liposome with the cell membrane and subsequent release of the nucleic acid contained within. However, several disadvantages are associated with use of liposomes for the delivery of nucleic acids. Liposomes are not effective for nucleic acid delivery to all cell types. Often high doses of nucleic acid are required for successful delivery. Additionally, liposomes lack selectivity and can bind plasma proteins and the extracellular matrix thus never reaching their target cells.

[0009] Nucleic acids can also be integrated within a viral genome and delivered to target cells through viral infection. Adenovirus and retrovirus are commonly used for this purpose. The size of nucleic acid to be delivered by viral vector is limited to approximately 7-8 kb. Additionally, viral genes are also delivered with the nucleic acid which can lead to undesirable side effects including; immunogenicity, fixation of complement, poor-target selectivity and potential toxicity. It is also difficult to produce virus in the quantities necessary for use with delivery methods.

[0010] Delivery can also be enhanced by conjugation of the nucleic acid with specific peptides. Peptides containing aromatic amino acids (phenylalanine, tyrosine, tryptophan) are useful for this purpose. Additionally, viral peptides, such as fusogenic peptides derived from Staphylococcal Protein A enhance membrane fusion and thus can increase the efficiency of delivery. However, peptide-enhanced delivery is not effective for all types of cells.

[0011] Since many disadvantages remain associated with all of the compositions and methods currently employed for in vivo delivery discussed in the above paragraphs, there is clearly a need for improved compositions and methods for delivery of nucleic acids.

[0012] The delivery compositions and methods noted above exhibit a variety of disadvantages, however one disadvantage common to all is the lack of selectivity. Without selectivity delivery to specific cells is impossible. In an attempt to improve selectivity, researchers have attached molecules having the ability to target specific cell types to the surface of carriers, such as liposomes and polymeric cations. Examples of these types of molecules that can be attached to carriers are antibodies, cell adhesion peptides, hormones and cell-specific ligands. However, use of these molecules has not significantly improved selectivity of delivery.

[0013] Attachment of nucleic acids to multiple protein ligands that are each capable of specifically targeting cells is one approach to increasing selectivity of nucleic acid delivery methods, thereby increasing the efficiency of transport and thus increasing the resulting gene expression. A protein ligand is a soluble protein molecule that exhibits specific binding of high affinity for another molecule, for example, epidermal growth factor (EGF) is a ligand which specifically binds epidermal growth factor receptor (EGFR) on cellular surfaces with high affinity. Protein ligands are often internalized into the cell upon binding to their receptors, thus ligands can be used as vectors to carry nucleic acids specifically into target cells.

[0014] The present inventor has devised unique integrated moieties containing multiple ligands in linkage with at least one nucleic acid. These unique integrated moieties are capable of increasing the selectivity of nucleic acid delivery by specifically targeting multiple cell types using multiple ligands, thereby simultaneously increasing the efficiency of nucleic acid transport and the resulting gene expression. Use of these unique moieties for delivery of nucleic acids enables an increase in selectivity which represents a difference in kind as compared to the selectivity of compositions available in the prior art.

[0015] Although researchers have heretofore constructed compositions containing a single ligand linked to a carrier that targets an individual cell surface molecule, they have failed to produce a composition capable of increasing the selectivity of nucleic acid delivery by specifically targeting multiple cell types using multiple ligands, thereby simultaneously increasing the efficiency of nucleic acid transport and the resulting gene expression. What is lacking in the art is a composition capable of increasing the selectivity of nucleic acid delivery by specifically targeting multiple cell types using multiple ligands, thereby simultaneously increasing the efficiency of nucleic acid transport and the resulting gene expression.

DESCRIPTION OF THE PRIOR ART

[0016] As is referred to above, there are several broad categories of compositions and methods currently employed for in vivo delivery of nucleic acids. Representative examples include:

[0017] U.S. Pat. No. 5,972,707 (Roy et al.) discloses a gene delivery system containing nanospheres made of enzymatically degradable polymeric cations complexed with nucleic acid. Targeting ligands can be attached directly or indirectly through a linking agent to the nanospheres disclosed by Roy et al. Roy et al. discloses a nanosphere with an attached transferrin ligand in Example 2 of U.S. Pat. No. 5,972,707. Roy et al. does not disclose or suggest attachment of multiple ligands capable of selectively targeting multiple cell types.

[0018] U.S. Pat. No. 6,051,429 (Hawley-Nelson et al.) discloses a composition useful for nucleic acid delivery wherein peptides are bound to the nucleic acid prior to addition of the transfection agent (cationic lipids or dendrimers). Hawley-Nelson et al. discloses four broad categories of peptides that can be used in their composition; fusagenic, membrane-permeabilizing, receptor-ligand and sub-cellular localization (nuclear or mitochondrial). These peptides increase the efficiency of transfection and can also be bound to the transfection agent according to the protocol taught by Hawley-Nelson et al. Hawley-Nelson et al. does not disclose or suggest attachment of multiple peptides capable of selectively targeting multiple cell types.

[0019] U.S. Pat. No. 6,312,727 (Schacht et al.) discloses a composition useful for delivery of nucleic acids containing synthetic polymer-based carriers. The carrier of Schacht et al. is made by self-assembly of the nucleic acid with cationic polymer material so as to condense the nucleic acid and form a polyelectrolyte complex and reacting the complex with a hydrophilic polymer material which binds to the complex thus stabilizing and protecting the complex. Schacht et al. discloses that transferrin can be added to the complex to increase the transfection efficiency. Schacht et al. does not disclose or suggest attachment of multiple molecules capable of selectively targeting multiple cell types.

[0020] U.S. Pat. No. 6,387,700 (Rice et al.) discloses a composition useful for delivery of nucleic acids containing low molecular weight nucleic acid condensing agents, such as aromatic amino acid (phenylalanine, tyrosine, tryptophan) containing peptides. Rice et al. disclose a general teaching wherein ligands selected to target specific cell surface receptors may be attached to the condensing agent in order to achieve site-specific targeting. However, Rice et al. does not disclose or suggest any specific types of ligands nor do they disclose or suggest the use of multiple ligands.

[0021] It is important to note that the compositions disclosed in the above references teaching attachment of specific molecules to nucleic acid carriers involve a single ligand targeting a nucleic acid to a single receptor, this is in contrast to the compositions of the instant invention wherein multiple ligands target a nucleic acid to multiple receptors, thus enabling multiple cell types to produce the encoded protein. None of the above references disclose or suggest a composition capable of increasing the selectivity of nucleic acid delivery by specifically targeting multiple cell types using multiple ligands, thereby simultaneously increasing the efficiency of nucleic acid transport and the resulting gene expression.

SUMMARY OF THE INVENTION

[0022] The instant invention provides compositions capable of increasing the selectivity of nucleic acid delivery by specifically targeting multiple cell types using multiple ligands, thereby simultaneously increasing the efficiency of nucleic acid transport and the resulting gene expression.

[0023] As used herein the term “nucleic acid” includes both DNA and RNA. Any nucleic acid is considered to be encompassed within the scope of the instant invention. The DNA sequences (SEQ ID NOS:9 and 11) encoding the human antibody against digoxin were used in the experimental examples herein described. However, it is noted that the use of the compositions of the instant invention to deliver DNA sequences encoding the human antibody against digoxin is an illustrative example only and is not intended to limit the compositions to delivery of DNA sequences encoding the human antibody against digoxin. The compositions of the instant invention contain only human proteins and thus would not elicit an immune response when administered to a human host. The compositions of the instant invention can be used to deliver any nucleic acid to a wide variety of cells and tissues without eliciting an immune response.

[0024] As used herein the term “ligand” refers to a molecule that exhibits specific binding of high affinity for another molecule and upon binding with that molecule is internalized into the cellular interior. Any such ligand is intended to be encompassed within the scope of the instant invention. Illustrative, albeit non-limiting examples of ligands known and commonly used in the art are antibodies, cell adhesion molecules, hormones and cell-specific ligands. Researchers can select ligands and nucleic acid sequences to design a composition according to preferred use. Particularly preferred ligands for use are the cell-specific ligands, human epidermal growth factor (EGF), human vascular endothelial growth factor (VEGF) and human transferrin. The epidermal growth factor receptor (EGFR) is expressed by epithelial and epidermal cells and shows an increase in expression on the cellular surface of many types of tumor cells. The vascular endothelial growth factor receptor (VEGFR) is expressed by endothelial cells of non-resting blood vessels, which are particularly abundant in rapidly proliferating tumors. The transferrin receptor is ubiquitously expressed and shows an increase in expression on the cellular surface of actively proliferating cells, in particular in tumor tissues which often contain actively proliferating cells. Accordingly, EGF functions as a vector for delivery of nucleic acids to cells expressing the EGFR, VEGF functions as a vector for delivery of nucleic acids to cells expressing the VEGFR and transferrin functions as a vector for delivery of nucleic acids to cells expressing the transferrin receptor. Although each of these ligands (EGF, VEGF and transferrin) can be used to deliver nucleic acids to any cell expressing their respective complementary receptors (EGFR, VEGFR and the transferrin receptor), these ligands are particularly useful for cancer therapeutics, since these receptors are often highly expressed in tumor tissues.

[0025] Tumors are recognized as comprising a mixed population of cells including both neoplastic cells and normal endothelial cells. In order for a tumor to grow, new blood vessels are required to provide nutrients and to remove waste. Tumor cells secret growth factors to induce the formation of new blood vessels. These newly formed blood vessels comprise normal cells and are characterized by the expression of surface molecules that are not present on resting endothelium, for example vascular endothelial growth factor receptor (VEGFR). Additionally, the EGFR has been identified as a cell surface receptor that is overexpressed on many types of neoplastic cells and expression of the transferrin receptor is increased in actively proliferating cells, which may be both the neoplastic cells and endothelial cells of the tumor vasculature. Since certain particular embodiments of the compositions of the instant invention contain ligands capable of targeting both neoplastic cells and the endothelial cells of the tumor vasculature, these compositions can be used to deliver nucleic acids encoding therapeutic molecules to both cellular populations of the tumor mass.

[0026] Accordingly in certain embodiments, the compositions of the instant invention contain a ligand such as human vascular endothelial growth factor (VEGF) or human epidermal growth factor (EGF) or contain both human VEGF and human EGF and at least one nucleic acid operatively linked to a human transferrin ligand, wherein said human VEGF binds to human VEGF receptors on endothelial cell surfaces of intratumoral blood vessels, said human EGF binds to human EGF receptors when present on cell surfaces of tumor cells and said human transferrin binds human transferrin receptors on endothelial cell surfaces of intratumoral blood vessels and cell surfaces of tumor cells. FIG. 1 shows a schematic diagram of several embodiments of the compositions described herein.

[0027] As used herein, the term vascular endothelial growth factor (VEGF) encompasses VEGF and isolated peptide fragments or biologically active portions thereof, analogues of VEGF and any biologically active portion thereof and any molecules and portions of molecules having the biological activity of VEGF.

[0028] As used herein, the term epidermal growth factor (EGF) encompasses EGF and isolated peptide fragments or biologically active portions thereof, analogues of EGF and any biologically active portion thereof and any molecules and portions of molecules having the biological activity of EGF.

[0029] As used herein, the term transferrin encompasses transferrin and isolated peptide fragments or biologically active portions thereof, analogues of transferrin and any biologically active portion thereof and any molecules and portions of molecules having the biological activity of transferrin.

[0030] As used herein, the term “bioactivity” refers to the ability of a ligand to bind to its complementary receptor thus enabling internalization of the ligand into the cellular interior.

[0031] As used herein, the term “biologically active portion” refers to the portion of a ligand that has the ability to bind to its complementary receptor thus enabling internalization of the ligand into the cellular interior.

[0032] The compositions of the instant invention can be added to a pharmacologically effective amount of a carrier to provide pharmaceutical compositions for administration to an animal host, including administration to a human patient. Illustrative, albeit non-limiting examples of carriers known in the art and suitable for use with the instant invention are water, saline solutions and dextrose solutions. A particularly preferred carrier is saline, the use of which is illustrated in the examples herein.

[0033] Accordingly, it is an objective of the instant invention to provide a compound comprising at least one ligand and at least one nucleic acid each operatively linked to transferrin wherein said at least one ligand binds complementary receptors where expressed on cell surfaces and said transferrin binds transferrin receptors where expressed on cell surfaces.

[0034] It is another objective of the instant invention to provide a conjugate consisting essentially of at least one ligand and at least one nucleic acid each operatively linked to transferrin wherein said at least one ligand binds complementary receptors where expressed on cell surfaces, and said transferrin binds transferrin receptors where expressed on cell surfaces.

[0035] It is another objective of the instant invention to provide a compound comprising human vascular endothelial growth factor (VEGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human VEGF binds human VEGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.

[0036] It is yet another objective of the instant invention to provide a conjugate consisting essentially of human vascular endothelial growth factor (VEGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human VEGF binds human VEGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.

[0037] It is another objective of the instant invention to provide a compound comprising human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human EGF binds human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.

[0038] It is another objective of the instant invention to provide a conjugate consisting essentially of human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human EGF binds human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.

[0039] It is yet another objective of the instant invention to provide a compound comprising human vascular endothelial growth factor (VEGF), human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferrin, wherein said human VEGF binds to human VEGF receptors where expressed on cell surfaces, said human EGF binds to human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.

[0040] It is another objective of the instant invention to provide a conjugate consisting essentially of human vascular endothelial growth factor (VEGF), human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferring wherein said human VEGF binds to human VEGF receptors on cell surfaces, said human EGF binds to human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.

[0041] It is still another objective of the instant invention to provide pharmaceutical compositions comprising the compounds and compositions of the instant invention and a pharmacologically effective amount of a carrier.

[0042] Other objectives and advantages of this invention will become apparent from the following description taken in conjunction with the accompanying drawings wherein are set forth, by way of illustration and example, certain embodiments of this invention. The drawings constitute a part of this specification and include exemplary embodiments of the present invention and illustrate various objects and features thereof.

BRIEF DESCRIPTION OF THE FIGURES

[0043]FIG. 1 shows a diagrammatic presentation of several embodiments of the compositions described herein.

[0044]FIG. 2 shows a schematic presentation of the cloning steps necessary to produce the DNA vectors utilized in the experimental examples described herein.

[0045]FIG. 3 shows a graphical presentation of Breast Cancer Bone Metastatsis (BCBM) volumes in SCID mice.

[0046]FIGS. 4A-4B show immunohistochemistry of BCBM specific for EGFR (epidermal growth factor receptor). FIG. 4A shows a histologic section stained with antibody (TS40) specific for the human cell surface EGFR. FIG. 4B is a micrograph showing an isolated EGFR⁺ breast cancer cell in the bone marrow.

[0047]FIG. 5 is a micrograph showing blood vessels of human origin in the BCBM tumors in SCID mice.

[0048]FIG. 6 shows a graphical presentation of the serum level of anti-digoxin antibody achieved in the experimental SCID mice (non-tumor bearing).

DEFINITIONS

[0049] The following list defines terms, phrases and abbreviations used throughout the instant specification. Although the terms, phrases and abbreviations are listed in the singular tense the definitions are intended to encompass all grammatical forms.

[0050] As used herein, the abbreviation “EGF” refers to epidermal growth factor.

[0051] As used herein, the abbreviation “EGFR” refers to epidermal growth factor receptor.

[0052] As used herein, the abbreviation “VEGF” refers to vascular endothelial growth factor.

[0053] As used herein, the abbreviation “VEGFR” refers to vascular endothelial growth factor receptor.

[0054] As used herein, the abbreviation “BCBM” refers to breast cancer bone metastatsis.

[0055] As used herein, the abbreviation “PEG” refers to polyethylene glygol.

[0056] As used herein, the abbreviation “TF” refers to transferrin.

[0057] As used herein, the abbreviation “SA” refers to streptavidin.

[0058] As used herein, the abbreviation “TF/SA” refers to a composition comprising transferrin linked to streptavidin.

[0059] As used herein, the abbreviation “MBS” refers to m-maleimidobenzoyl N-hydroxysuccinimide ester.

[0060] As used herein, the abbreviation “HPLC” refers to high performance liquid chromatography.

[0061] As used herein, the abbreviation “RP-HPLC” refers to reverse phase high performance liquid chromatography.

[0062] As used herein, the abbreviation “NHS” refers to N-hydroxysuccinimide.

[0063] As used herein, the abbreviation “TFA” refers to trifluoroacetic acid.

[0064] As used herein, the abbreviation “PBS” refers to phosphate buffered saline.

[0065] As used herein, the abbreviation “SCID” refers to a type of transgenic mouse that is severe combined immuno-deficient.

[0066] As used herein, the term “selective delivery” is defined as delivery which is targeted to a specific cell type for the purpose of avoiding uniform or even delivery to all cell types.

[0067] As used herein, the term “selective concentration” is defined as concentrating a substance, such as nucleic acid, to a specific area for the purpose of avoiding uniform or even concentration of a substance in all areas.

[0068] As used herein, the term “nucleic acid” is meant to encompass both DNA and RNA.

[0069] As used herein, the term “ligand” refers to a molecule that exhibits specific binding of high affinity for another molecule and upon binding with that molecule is internalized into the cellular interior. An illustrative, albeit non-limiting example of how the term “ligand” is used in the context of the instant specification is a protein ligand binding to a cell surface receptor, such as EGF binding to the EGFR.

[0070] As used herein, the term “receptor” refers to a molecule that exhibits specific binding of high affinity for its complementary ligand. An illustrative, albeit non-limiting example of how the term “receptor” is used in the context of the instant specification is a cell surface receptor binding to a ligand, such as the EGFR binding the EGF.

[0071] As used herein, the term “complementary receptor” refers to the receptor a ligand specifically binds with high affinity, for example, the EGFR is the complementary receptor for EGF.

[0072] As used herein, the term “target” refers to a specific molecule expressed on the cellular surface such as a receptor to which a specific moiety can be directed, for example the EGFR is a target for EGF. As used herein “target” can also refer to a cell or tissue, for example, a cell or tissue expressing the EGFR is a target for EGF.

[0073] As used herein, the term “targeting agent” refers to a specific molecule that binds to a complementary molecule expressed on the cellular surface such as a ligand, for example EGF is a targeting agent for the EGFR.

[0074] As used herein, the phrase “multi-targeted” refers to the ability of a protocol to target at least two disease elements, for example, the composition of the instant invention can be used to target an entire tumor mass by using EGF to target the tumor cells (or by using VEGF to target the endothelial cells of the tumor vasculature) and by using transferrin to target both the tumor cells and the endothelial cells of the tumor vasculature.

[0075] As used herein, the phrase “disease elements” refers to the separate targets or elements that contribute to result in an entire disease state, for example, malignant cells and endothelial cells are each separate disease elements in cancer pathology.

[0076] As used herein, the term “VEGF” refers to a glycosylated polypeptide that serves as a mitogen to stimulate vascular development. VEGF imparts activity by binding to vascular endothelial cell plasma membrane-spanning tyrosine kinase receptors (VEGFR's) which then activates signal transduction.

[0077] As used herein, the term “VEGFR” refers to a vascular endothelial cell plasma membrane-spanning tyrosine kinase receptor which binds VEGF thus exerting a mitogenic signal to stimulate vascularization of tissues.

[0078] As used herein, the term vascular endothelial growth factor (VEGF) encompasses VEGF and isolated peptide fragments or biologically active portions thereof, analogues of VEGF and any biologically active portion thereof and any molecules and portions of molecules having the biological activity of VEGF.

[0079] As used herein, the term “EGF” refers to a mitogenic polypeptide that exhibits growth stimulatory effects for epidermal and epithelial cells. EGF imparts activity by binding to epidermal and/or epithelial cell plasma membrane-spanning tyrosine kinase receptors (EGFR's) which then activates signal transduction.

[0080] As used herein, the term “EGFR” refers to a epidermal and/or epithelial cell plasma membrane-spanning tyrosine kinase receptor which binds EGF thus exerting a mitogenic signal.

[0081] As used herein, the term epidermal growth factor (EGF) encompasses EGF and isolated peptide fragments or biologically active portions thereof, analogues of EGF and any biologically active portion thereof and any molecules and portions of molecules having the biological activity of EGF.

[0082] As used herein, the term “transferrin” refers to a vertebrate glycoprotein that functions to bind and transport iron.

[0083] As used herein, the term “transferrin receptor” refers to a receptor expressed on the surface of cells functioning to capture and bind iron saturated transferrin. Expression of the transferrin receptor is increased in cells which are actively proliferating.

[0084] As used herein, the term transferrin encompasses transferrin and isolated peptide fragments or biologically active portions thereof, analogues of transferrin and any biologically active portion thereof and any molecules and portions of molecules having the biological activity of transferrin.

[0085] As used herein, the term “host” refers to any animal having cells to which nucleic acids can be delivered.

[0086] As used herein, the term “tumor tissue” refers to all of the cellular types which contribute to formation of a tumor mass, including tumor cells and endothelial cells, for example, the tumor tissue includes tumor cells and blood vessels.

[0087] As used herein, the term “tumor mass” refers to a foci of tumor tissue.

[0088] As used herein, the term “inhibition” refers to retarding the growth of a tumor mass.

[0089] As used herein, the term “bioactivity” refers to the ability of a ligand to bind to its complementary receptor thus enabling internalization of the ligand into the cellular interior.

[0090] As used herein, the term “biologically active portion” refers to the portion of a ligand that has the ability to bind to its complementary receptor thus enabling internalization of the ligand into the cellular interior.

[0091] As used herein, the phrases, “tumor vasculature”, “tumor endothelium” and “tumor vessels” all refer to the circulatory vessels which supply the tumor tissue with blood.

[0092] As used herein, the term “angiogenesis” refers to the process by which tissues become vascularized. Angiogenesis involves the proteolytic degradation of the basement membrane on which the endothelial cells reside followed by the chemotactic migration and mitosis of the endothelial cells to support a new capillary shoot.

[0093] As used herein, the term “linker” refers to the molecules which join the ligands of the composition of the instant invention together to form a single compound; for example, EGF-PEG attached to biotin links streptavidin attached to transferrin.

[0094] As used herein, the phrase “operatively linked” means that the linkage does not destroy the functions of each of the separate elements of the composition of the instant invention, for example, when linked together by a linker to form the single compound of the instant invention the ligands retain the ability to bind their complementary receptors.

[0095] As used herein, the term “carrier” refers to a pharmaceutically inert substance that facilitates delivery of an active agent to a host, for example, as is shown in the experiments described herein, saline functions as a carrier for delivery of the compositions of the instant invention to the mouse host.

[0096] As used herein, the phrase “pharmacologically effective amount of a carrier” refers to an amount of a carrier that is sufficient to effectively deliver an active agent to a host.

[0097] As used herein, the term “pharmaceutical composition” refers to the compositions of the instant invention combined with a pharmacologically effective amount of a carrier.

[0098] The phrases “tumor endothelium”, “tumor vasculature” and “tumor vessels” are used interchangeably herein.

[0099] The terms “tumor cell”, “neoplastic cell” and “cancer cell” are used interchangeably herein.

[0100] As used herein, the term “compound” refers to a substance containing at least two distinct elements to which an unlimited number of other elements can be added.

[0101] As used herein, the term “conjugate” refers to a substance containing at least two distinct elements and a defined number of additional elements.

[0102] As used herein, the term “composition” is intended to encompass both a compound and a conjugate

DETAILED DESCRIPTION OF THE INVENTION

[0103] Experimental Procedures

[0104] Sequences

[0105] The following nucleic acid sequences and corresponding amino acid sequences were used to generate the DNA and polypeptides used in the experiments described herein. Homo sapiens (human) VEGF165 (vascular endothelial growth factor isoform 165) nucleic acid sequence is disclosed as SEQ ID NO:1 and translates into VEGF165 protein disclosed as amino acid sequence SEQ ID NO:2. Homo sapiens (human) transferrin nucleic acid sequence is disclosed as SEQ ID NO:3 and translates into transferrin protein disclosed as amino acid sequence SEQ ID NO:4. Homo sapiens (human) EGF (epidermal growth factor) nucleic acid sequence is disclosed as SEQ ID NO:5 and translates into EGF protein disclosed as amino acid sequence SEQ ID NO:6. Homo sapiens (human) anti-digoxin antibody heavy chain nucleic acid sequence is disclosed as SEQ ID NO:9 and translates into anti-digoxin antibody heavy chain protein disclosed as SEQ ID NO:10. Homo sapiens (human) anti-digoxin antibody light chain nucleic acid sequence is disclosed as SEQ ID NO:11 and translates into anti-digoxin antibody light chain protein disclosed as SEQ ID NO:12.

[0106] Linkers

[0107] When assembling compositions from multiple elements, elements are either linked directly through chemical conjugation (for example through reaction with an amine or sulfhydryl group) or are linked indirectly through molecules termed linkers. When selecting a linker it is important to choose the appropriate length and flexibility of linker in order to reduce steric hindrance between the elements of the composition. For example, if an element of a composition is brought into close physical proximity of another element by linkage, the function of either or both elements can be affected. Each element of the composition must retain its bioactivity, for example in the instant invention, each ligand must retain its ability to bind to its complementary receptor after linkage with the other ligands of the composition. Illustrative, albeit non-limiting examples of linkers are glycols, alcohols and peptides. Particularly preferred linkers are PEG (polyethylene glycol) and the peptide linker shown as SEQ ID NO:8 (use of each of these linkers is illustrated in the examples described herein).

[0108] Crosslinking of VEGF (and EGF) to a Biotinylated-Polylinker

[0109] EGF and VEGF are crosslinked to a biotinylated polylinker by carrying out the following protocol. The polylinker used consists of 15 amino acid residues shown as SEQ ID NO:8. The cDNA sequence encoding this polylinker is shown as SEQ ID NO:7. The first glycine residue at the N-terminal was biotinylated. EDC (1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide Hydrochloride) and NHS (N-Hydroxysuccinimide) were equilibrated to room temperature. 0.4 mg of EDC and 0.6 mg of NHS were added to 1 mg/ml of the polylinker peptide solution (in activation buffer: 0.1 M MES (2-[N-morpholino]ethane sulfonic acid), 0.5 M NaCl, pH 6.0) to a final concentration of EDC and NHS of 2 mM and 5 mM respectively. The reaction mixture was then held for 15 minutes at room temperature. 1.4 ul of 2-mercaptoethanol was then added (to a final concentration of 20 mM). The reaction mixture was then run through P2 gel filtration mini-column and eluted by the activation buffer. Fractions containing the protein were then pooled together. Equal mole:mole ratios of either VEGF or EGF protein were added to the pooled fractions and reacted for 2 hours at room temperature. Hydroxylamine was added to a final concentration of 10 mM and the VEGF-linker or EGF-linker was purified by P2 gel filtration mini-column.

[0110] Synthesis of TF/SA Composition

[0111] 8.84 mg of transferrin (TF) was thiolated by adding a 5-fold molar excess of 2-Iminothiolane hydrochloride (Traut's reagent) in pH 8.0, 0.16 M borate. Following 90 minutes at room temperature, the thiolated TF was desalted and concentrated by Centricon microconcentrators. Ellman's reagent (Pierce) was then used to demonstrate that a single thiol group was inserted on the surface of TF. 7 mg of streptavidin (SA) (in PBS) was activated by adding to a 20:1 molar ratio of m-maleimidobenzoyl N-hydroxysuccinimide ester (MBS)(stock at 1 mg/ml in dimethylformamide). After 20 minutes, the activated SA was desalted on a microconcentrator and immediately, the activated SA was added to a 10 molar excess of thiolated TF. They were mixed and then incubated at room temperature for 3 hours. Purification of the TF/SA composition was done by HPLC using TSK-G3000 column. The number of biotin binding sites per TF/SA composition was determined with ³H-biotin binding assay.

[0112] Conjugation of VEGF-Linker-Biotin (and EGF-Linker-Biotin) to TF-SA

[0113] VEGF-Linker-Biotin and EGF-Linker-Biotin are added to TF/SA by carrying out the following protocol. The composition of VEGF-Linker-biotin (or EGF-Linker-biotin) and TF/SA was prepared by mixing 5 nmol of VEGF-Linker-biotin (or 5 nmol of EGF-Linker-biotin) with 8 nmol of TF/SA (1:1.6 molar ratio). HPLC was then used to purify the VEGF-Linker-biotin-TF-SA composition (or EGF-Linker-biotin-TF-SA composition).

[0114] Conjugation of VEGF (and EGF) to PEG3400-Biotin

[0115] Alternatively to linkage with a peptide linker, VEGF and. EGF can also be linked to transferrin using PEG by carrying out the following protocol. NHS-PEG3400-biotin was obtained from Shearwater Polymers (Huntsville, Ala.), where NHS=N-hydroxysuccinimide and PEG3400=poly(ethylene glycol) of 3400 Da molecular mass. NHS-PEG3400-biotin (20 nmol in 310 μl of 0.05 M NaHCO3) was added in a 1:1 molar ratio to either VEGF or EGF (16 nmol in 250 μl of 0.05 M NaHCO3) followed by incubation at room temperature for 60 minutes. The mixture was then applied to two Sepharose 12 HR 10/30 FPLC columns in, series, followed by the elution in 0.01 M NaH2PO4/0.15 M NaCl/pH 7.5 at a flow rate of 0.7 mL/minute for 120 minutes. Fraction(s) that contained VEGF or EGF bound to PEG3400-biotin moiety were pooled together.

[0116] Conjugation of VEGF-PEG3400-Biotin (and EGF-PEG3400-Biotin) to TF-SA

[0117] Following reaction of EGF and/or VEGF with NHS-PEG3400-biotin and transferrin with streptavidin, both compositions were purified by HPLC. The EGF (and/or VEGF)-NHS-PEG3400-biotin and TF/SA compositions were then mixed (1:1.6 molar ratio). HPLC was then used to purify the EGF (and/or VEGF)-NHS-PEG3400-biotin-TF-SA compositions.

[0118] Synthesis of Biotinylated Polylysine for Nucleic Acid Carrier and Attachment to VEGF-TF (and/or EGF-TF)

[0119] After attachment of the ligands (such as, EGF and VEGF) to the transferrin ligand, the nucleic acid was condensed and attached to the transferrin ligand according to the following; protocol. Two polylysine (PLL) peptides were used for the DNA molecule to form a complex: Cys-Trp-Lys₁₉ (K₁₉, BioPeptide, San Diego, Calif.) and Lys₁₅₀ (K₁₅₀, average molecular weight of 20,000, Sigma, St Louis, Mo.). Biotin reagents for peptide modification were purchased from Pierce (Rockford, Ill.). Peptide K₁₉ was modified with a biotin group through the terminal cysteine residue by reaction of the sulfhydryl group with the iodoacetyl group of the biotinylation reagent, EZ-link-PEO-iodoacetyl-biotin. The peptide K₁₉ (10 mg) was dissolved in 90 μL of buffer (50 mM Tris, 5 mM EDTA, pH=8.3) that was previously bubbled with nitrogen gas. The EZ-link-PEO-iodoacetyl-biotin (48 mg) was also dissolved in 200 μL of buffer (0.1 M sodium phosphate, 5 mM EDTA, pH=6.0). The biotin solution was added dropwise to the peptide solution, mixed gently and incubated for 90 minutes. The starting peptide solution and the reaction mixture were analyzed by HPLC to determine if the reaction had gone to completion. The starting peptide solution and the reaction mixture were resolved by injecting 50 μg through a C18 RP-HPLC column eluted with water (0.1% trifluoroacetic acid) and an acetonitrile gradient (0.1% TFA, 0 to 95% over 50 minutes at 60° C.) while detecting the absorbance at 260 nm. For purification, sephadex (G15) was equilibrated in deionized water for 30 minutes prior to packing in a glass column (2 cm diameter×12 cm height). The reaction mixture was passed though the column using deionized water. Thirty fractions were collected, and the presence of the tryptophan side chain was examined by measuring the absorbance at 260 nm (Beckman Instruments Inc., Fullerton, Calif.). The fractions with the greatest absorbance at 260 nm were lyophilized. The purified biotinylated peptide (K₁₉-B) was stored as a powder at −20° C.

[0120] The peptide K₁₅₀ was biotinylated using succinimide ester (NHS)/amine chemistry. K₁₅₀ (10 mg) was dissolved in 1 mL of phosphate buffered saline (PBS, pH=7) and EZ-link-Sulfo-NHS-LC-biotin (2.8 mg) was added directly to the solution, mixed gently and incubated for 2 hours at 4° C. The reaction mixture was purified using dialysis cassettes immersed in deionized water. The dialyzed product was further purified using a monomeric avidin column to separate the biotinylated components from nonbiotinylated species. The biotinylated product was eluted with 10 mL of a 10 mM biotin solution and dialyzed to remove the unconjugated biotin. The purified biotinylated peptide (K₁₅₀-B) was then lyophilized and stored as a powder at −20° C.

[0121] The composition of polylysine-biotin and TF/SA was prepared by mixing polylysine-biotin with TF/SA (1:1.6 molar ratio). HPLC was then used to purify the polylysine-biotin-TF-SA composition. The reaction mixture was applied to a TSK-gel G3000 SWXL HPLC gel filtration column, followed by elution in 0.01 M Na₂HPO₄/0.15 M NaCl/pH 7.4/0.05% Tween-20 at a flow rate of 0.5 mL/min for 40 minutes, and 0.5 mL fractions were collected and lyophilized and stored as a powder at −20° C.

[0122] Digoxin is a cardiac glycoside found in the leaves of the foxglove plant group. Digoxin is used for long-term treatment of chronic heart weakness and defective heart valves. However, if administered in incorrect dosages, digoxin can be highly toxic. Anti-digoxin antibodies are often used to counter these toxic effects. (see Concise Encyclopedia Biochemistry and Molecular Biology, Third Edition, revised and expanded by Thomas A. Scott and E. Ian Mercer, Walter de Gruyter publisher, Berlin and New York, 1997, page 173, for a discussion of digoxin).

[0123] In order to test the efficacy of the compositions of the instant invention, nucleic acid encoding the human anti-digoxin antibody (IgG) was selected for delivery to SCID mice. Nucleic acid sequence, SEQ ID NO:9, encodes the heavy chain (including constant and variable regions) of the human anti-digoxin antibody and nucleic acid sequence, SEQ ID NO:11, encodes the light chain of the human anti-digoxin antibody (including constant and variable regions). FIG. 2 shows a schematic presentation of the cloning steps used to generate the DNA vectors containing SEQ ID NO:9 and SEQ ID NO:11 which were used in the experiments illustrated herein. SEQ ID NO:9 was inserted into the multiple cloning site of the pVAX1 plasmid to form the first vector (heavy chain) and SEQ ID NO:11 was inserted into the multiple cloning site of the pVAX1 plasmid to form the second vector (light chain). Symbols and abbreviations shown in FIG. 2 are defined as follows: IgH, refers to cDNA encoding the heavy chain of the immunoglobulin antibody against digoxin (SEQ ID NO:9); IgL, refers to cDNA encoding the light chain of the immunoglobulin antibody against digoxin (SEQ ID NO:11); T7, refers to the T7 promoter useful for achieving efficient transcription; CMV, refers to the human cytomegalovirus immediate-early promoter/enhancer useful for achieving efficient high-level expression of the sequences encoded in the multiple cloning site of the plasmids; BGH, refers to the bovine growth hormone polyadenylation (pA) signal useful for achieving efficient transcription termination and polyadenlylation of mRNA; kanamycin, refers to the gene encoding kanamycin resistance useful as a selection marker in E. coli to select cells expressing the cloned sequences and pUC ori, refers to the pUC-derived origin of replication useful for achieving high-copy number plasmid replication and growth in E. coli.

[0124] Following preparation of the vectors, 50 μg of each DNA vector (250 μg/ml) was mixed with polylysine-biotin-TF-SA.

[0125] Experimental Mice

[0126] Severe combined immuno-deficient C.B.-17 scid/scid (SCID) mice were bred and maintained according to the protocol of Sandhu et al. (Critical Reviews in Biotechnology 16(1):95-118 1996). Mice were used when 6-8 weeks old and were pre-treated with a dose of 3 Gy γ-radiation administered from a ¹³⁷CS source (Gamacell, Atomic Energy of Canada Ltd.Commercial Products). The irradiated SCID mice receive intraperitoneal injection of 20 μl ASGM1 sera diluted to 100 μl with saline, 4 hours pre-bone transplantation and every 7 days thereafter for the duration of the experiments.

[0127] The following groups of experiments were undertaken in order to determine the effectiveness of the EGF and VEGF ligands in cancer therapeutics.

[0128] Experimental Tumors

[0129] The compositions of the instant invention are effective when used to target either an EGFR⁺ tumor or an EGFR⁻ tumor since the transferrin moiety targets those tumor cells that are EGFR⁻. A bone metastatic focus of a primary EGFR⁺ breast tumor was used in the experimental examples herein described. However, it is noted that the use of the compositions of the instant invention in breast tumors is an illustrative example only and is not intended to limit the use of the compositions to breast tumors. The compositions of the instant invention can be used to deliver nucleic acids to any cells which are positive for the expression of at least one of the cell surface receptors described herein (the transferrin receptor, the EGFR and the VEGFR).

[0130] Implantation of Human Breast Cancer Bone Metastasis in SCID Mice

[0131] Breast cancer bone metastasis (BCBM) specimens (n=20, JJ1 to JJ20) were obtained from female patients (age range 40-68 years) undergoing total hip joint replacement due to BCBM mediated bone osteolysis. The majority (70%) of the BCBM used in these experiments were infiltrative ductal carcinoma and each specimen was assigned a number JJ1 to JJ20. Normal cancellous bone was obtained from healthy adult patients (age range 59-80 years) undergoing total hip joint replacement for the treatment of degenerative osteoarthritis. The BCBM was obtained from the proximal femur, morcellized using a rongeur and maintained under sterile conditions in RPMI (1640) medium (Gibco BRL, Burlington Ontario, Canada). Transplantation of the normal bone and BCBM into mice was performed within 2 hours of procurement, under a general anesthetic (intramuscular administration of Xylazine (4 μl/20 g mouse), and Ketamine (4 μl/20 g mouse) in 40 μl of 0.9% sodium chloride) under sterile conditions. Morcellized normal bone (Bone-SCID mice), and BCBM. (BCBM-SCID mice), approximately 0.121 cm³ per mouse, was transplanted subcutaneously over the left flank in SCID mice (n=30).

[0132] Tumor Measurement

[0133] BCBM volumes were measured every 14 days for, 20 weeks to assess tumor growth in SCID mice as described by Osborne et al. (Cancer Research 45:584-590 1985). The data shows that in contrast to the similar growth rate of breast cancer cell lines in immunodeficient mice the growth pattern of BCBM specimens varies in SCID mice (see FIG. 3). Results showed JJ5 gave the best growth of the tumor, thus it was chosen as the surgical specimen for use in subsequent in vitro cell studies and in vivo animal experiments.

[0134] Cell Culture Studies

[0135] Measurement of EGF-¹¹¹In-Labeled Transferrin Composition Binding to Breast Cancer Cells

[0136] Transferrin was radiolabled at the iron-binding sites in the following experiments. Methods of radiolabeling and ions useful for radiolabeling are commonly known in the art and one of ordinary skill in the art would be familiar with them.

[0137] Breast cancer cells express up to 100-fold higher levels of EGFR than do normal epithelial tissues. EGFR expression in breast cancer bone metastasis biopsies ranged from 1-1300 fmol/mg membrane protein (approximately 400-1,000,000 receptors/cell) and was associated with high relapse rate and poor long term survival. Normal epithelial cells express <10⁴ receptors/cell.

[0138] For the normal breast cell line HBL-100, 8000 EGFR/cell has been reported. The expression of EGFR in breast cancer cell lines has a reported range of 800 EGFR/cell for MCF-7 cells to 10⁶ EGFR/cell for MDA-MB-468 cells. The liver is the only normal tissue exhibiting moderate levels of EGFR (8×10⁴ to 3×10⁵ receptors/cell) likely reflecting its role in the elimination of EGF from the blood. Utilizing the Auger electron emitter ¹¹¹In was used in the initial experiments to illustrate the utility of the invention using EGF-¹¹¹In-labeled transferrin compositions. The EGF-¹¹¹In-labeled transferrin (0.25-80 ng) was incubated with 1.5×10⁶ cells/dish JJ5 Breast Cancer (prepared from BCBM JJ5) cells in 1 mL of 0.1% human serum albumin in 35 mm multiwell culture dishes at 37° C. for 30 minutes. The cells were transferred to a centrifuge tube and centrifuged. The cell pellet was separated from the supernatant and counted in a g-scintillation counter to determine bound (B) and free (F) radioactivity. Non-specific binding was determined by conducting the assay in 100 nM hEGF. The kinetics of binding was determined by incubating 1 ng of EGF-¹¹¹In-labeled transferrin composition with 3×10⁶ JJ5 Breast Cancer cells at 37° C. and determining the proportion of radioactivity bound to the cells at various times up to 24 hours. Internalized fraction was measured by determining the proportion of radioactivity which could not be displaced from the cell surface by 100 nM hEGF. Cell-associated binding (surface-binding and intracellular accumulation) was expressed as a percentage of medium radioactivity bound per mg of cell study protein.

[0139] The affinity constant for binding of EGF-¹¹¹In-labeled transferrin composition to JJ5 cells was 8×10⁸ L/mol and the number of binding sites was 2.7×10⁶. EGF-¹¹¹In-labeled transferrin composition was rapidly bound by the breast cancer cells and retained for at least 24 hours. Over a 24 hour period at 37° C., <8% was lost from the cells in vitro.

[0140] The Growth Inhibition Assay of EGF-¹¹¹In-Labeled Transferrin Composition Against JJ5 Breast Cancer Cells

[0141] JJ5 breast cancer cells (prepared from BCBM JJ5) expressing approximately 10⁶ epidermal growth factor receptors/cell were incubated with EGF-¹¹¹In-labeled transferrin composition, unlabeled hEGF or ¹¹¹In-oxine, centrifuged to remove free ligand, then assayed and seeded (10⁶ cells/dish) into 35 mm culture dishes. Growth medium was added and the cells were cultured at 37° C./5% CO² for 4 days. The cells were then recovered by trypsinization and counted in a hemocytometer. Control dishes contained cells cultured in growth medium containing ¹¹¹In-DTPA or growth medium alone.

[0142] The growth inhibition assay of EGF-¹¹¹In-labeled transferrin composition (3.4 pCi/cell) achieved a 83% growth inhibition of the JJ5 cells compared to the medium control, whereas ¹¹¹In oxine (3.5 pCi/cell) which enters all the cells resulted in 91% growth inhibition.

[0143] Cytotoxicity Assay of EGF-¹¹¹In-Labeled Transferrin Composition Against JJ5 Breast Cancer Cells

[0144] JJ5 breast cancer cells were incubated with increasing amounts EGF-¹¹¹In-labeled transferrin composition or ¹¹¹In-oxine, centrifuged to remove free ligand, assayed and then seeded into 50 mm culture dishes. The number of cells seeded was varied from 3×10⁴ to 3×10⁶cells to obtain approximately 400 viable colonies/dish taking into account the plating efficiency and the expected level of cytotoxicity. Control dishes contained JJ5 breast cancer cells which were incubated with normal saline. Growth medium was added and the cells were cultured at 37° C./5% CO² for 14 days. The growth medium was removed and the colonies were stained with methylene blue (1% in a 1:1 mixture of ethanol and water) then washed twice. The number of colonies per dish was counted using a manual colony counter (Manostat Corp). The plating efficiency was calculated by dividing the number of colonies observed by the number of cells seeded in each dish. The surviving fraction at increasing amounts of EGF-¹¹¹In-labeled transferrin composition or ¹¹¹In-oxine was calculated by dividing the plating efficiency for dishes containing treated cells with that observed for control dishes with normal saline.

[0145] Using a colony-forming assay, the radiotoxicity of internalization for JJ5 breast cancer cells was evaluated. EGF-¹¹¹In-labeled transferrin compositions (8 pCi/cell) resulted in a 99% reduction in cell survival for JJ5 cells. ¹¹¹In-oxine was also radiotoxic with greater than 99% cell killing at <6 pCi/cell.

[0146] There are various advantages of using the compositions of the instant invention in cancer therapy. As seen from the foregoing data, EGF-¹¹¹In-labeled transferrin compositions are rapidly internalized by cancer cells. The internalization process for EGF-¹¹¹In-labeled transferrin compositions involves an active transport mechanism utilizing the EGFR binding domain of the composition, rather than simple diffusion across the cell membrane. This active transport mechanism for the composition probably also includes nuclear translocation, as for the case of EGF, which allows for a maximal radiation dose of Auger electrons to be delivered to the cell's DNA. The compositions of the instant invention employ human polypeptides and are not immunogenic in humans. EGF-¹¹¹In-labeled transferrin compositions have been shown to retain ¹¹¹In over a 24 hour period at 37° C., with <8% of ¹¹¹In radioactivity was lost from cells in vitro. These characteristics are important for cell killing.

[0147] Immunohistochemistry Staining and Measurement of EGF Receptor on BCBM Cells

[0148] Immunohistochemistry of BCBM pre-implanted into mice showed all the specimens (n=20) had breast cancer cells negative for the estrogen and progesterone receptors (data not shown). Normal human bone histological sections were used as controls, no staining was observed in these specimens (data not shown). BCBM were retrieved from the mice at 20 weeks. Histologic sections were fixed and prepared. Immunohistochemical staining was done using mouse anti-EGF-receptor monoclonal antibody (TS40). In contrast to the implants and the controls, 16 of the 20 BCBM specimens had breast cancer cells positive for human EGFR (see FIGS. 4A-B). The white arrow in FIG. 4A points out a dense mass of EGFR⁺ cells. The arrow in FIG. 4B points out an isolated EGFR⁺ cell in the bone marrow. Mean (±SDEV) expression levels of EGF receptor was measured on breast cancer cells from tumor JJ5 by radioligand binding assay 24 and were in the range of 2.7 (±0.8)×10⁶ receptors/cell.

[0149] Immunohistochemistry Staining of BCBM Human Blood Vessels

[0150] To evaluate the role of angiogenesis in the growth of human breast carcinoma, human BCBM surgical specimens were implanted in SCID mice. The breast tumors showed numerous blood vessels infiltrating the central mass of the tumors. In order to accurately assess the efficacy of treatment using the composition of the instant invention against human tumors, the blood vessels which developed in the BCBM in the mice must be of human origin. Immunohistochemical staining was done on BCBM sections using mouse anti-human CD34 antibody. Anti-human CD34 reacts specifically with human blood vessels and thus will not react with murine blood vessels. As shown in FIG. 5, these results clearly demonstrate the presence of human blood vessel angiogenesis within the tumor xenografts retrieved from SCID mice at 20 weeks. In FIG. 5, the arrow points out the dark blood vessels of human origin (stained with anti-human CD34), thus these specimens can be used to accurately assess the efficacy of the VEGF portion of the composition of the instant invention.

[0151] Animal Studies

[0152] The following experiment was undertaken to demonstrate that the compositions of the instant invention are capable of efficient delivery of nucleic acids to cells in vivo.

[0153] An EGF-PEG3400-biotin-TF-SA-DNA composition was prepared as described in the above experiments. The composition (250 μl) was injected intravenously into two groups of SCID mice; group one were normal SCID mice (non-tumor bearing) and group two were SCID mice implanted with JJ5 tumors (tumor-bearing). The control mice (also in two groups of tumor-bearing and non-tumor bearing) were administered the same amount of a similar composition, however the nucleic acid contained in this control composition did not encode for human anti-digoxin antibody. SCID mice serum was analyzed every two weeks using ELISA (Fishwild et al. Nature Biotechnology 14(7):845-851 1996) to determine the serum levels of human anti-digoxin antibody. Serum samples were exposed to plate-adsorbed digoxin-BSA, and biotinylated goat anto-mouse and anti-human heavy chain secondary antibodies were used to detect the hapeten-bound antibody. A strepavidin-alkaline phosphatase conjugate was used to quantitate anti-digoxin antibodies through hydrolysis of p-nitrophenylphosphate. FIG. 6 shows that the experimental group of mice produced the antibody for at least 112 days and in contrast very little antibody was detected in the serum of the control group of mice.

[0154] To examine if the anti-digoxin antibody seen in the serum was biologically active, mice survival studies using digoxin were done on all control and all experimental mice at 7 weeks post administration of the EGF-PEG3400-biotin-TF-SA-DNA composition. A general anesthetic [intramuscular administration of Xylazine (4 μl/20 g mouse), and Ketamine (4 μl/20 g mouse) in 40 μl of 0.9% sodium chloride] was administered to the mice under sterile conditions. The anesthetized mice were injected intravenously with 20 mg kg-1 of digoxin [purchased from Sigma USA] and animals were monitored continuously for 5 hours following digoxin administration. All the control mice (showing no serum anti-digoxin antibody) died from the digoxin overdose, in contrast the mice showing serum concentration of the anti-digoxin antibody survived the digoxin administration. These studies clearly demonstrate that the EGF-PEG3400-biotin-TF-SA-DNA composition of the instant invention is capable of efficient delivery of nucleic acids to cells in vivo and that the resulting protein produced in vivo is biologically active.

[0155] At the end of the digoxin-dosing experiments, DNA was isolated from the following tissues of the mice; lungs, liver, tumor, brain, kidney, blood, heart and muscle. Polymerase chain reaction was performed according to standard, molecular biology protocols found in Molecular Cloning:

[0156] A Laboratory Manual Authors: Joseph Sambrook and David W. Russell third edition 2001 on the isolated DNA for the presence of DNA coding for the anti-digoxin antibody. The antibody sequences were detected in the liver and the tumors in the tumor-bearing mice and only in the liver in the non-tumor bearing mice. This data suggests that the DNA is targeted to the liver by the VEGF, EGF and transferrin in the non-tumor bearing mice. In the tumor-bearing mice the VEGF, transferrin and EGF can target both the liver and tumor. Therefore this technology allows therapeutics coded by the DNA to be delivered directly to the tumors.

[0157] Antibodies of appropriate affinity and specificity have been shown capable of reversing advanced cardiac glycoside toxicity due to digoxin overdose. Without being bound by any particular theory, the reversal of digoxin effects by the digoxin antibody in the mice may be mediated by at least two mechanisms. First, the antibody may simply bind to cardiac glycoside and decrease the concentration of free digoxin in the serum, or second, the antibody may dislodge digoxin from its receptor.

[0158] In summary, the compositions of the instant invention enable delivery of nucleic acids to at least two appropriate target cells in vivo to exclusion of all other cell types with the resulting production of a biologically active protein in the target cells. The compositions of the instant invention are amenable for use with any nucleic acid sequence of interest and permit the introduction of these sequences into a variety of cells and tissues, however, these compositions are particularly useful for introduction of such therapeutic molecules as antibodies and cytotoxic molecules without elicitation of an immune response. As is evidenced by the experimental examples described and shown herein, the instant invention provides compositions capable of increasing the selectivity of nucleic acid delivery by specifically targeting multiple cell types using multiple ligands, thereby simultaneously increasing the efficiency of nucleic acid transport and the resulting gene expression.

[0159] All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the instant invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual patent and publication was specifically and individually indicated to be incorporated by reference.

[0160] It is to be understood that while a certain form of the invention is illustrated, it is not to be limited to the specific form or arrangement of parts herein described and shown. It will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification.

[0161] One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The oligonucleotides, peptides, polypeptides, biologically related compounds, methods, procedures and techniques described herein are presently representative of the preferred embodiments, are intended to be exemplary and are not intended as limitations on the scope. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.

1 12 1 495 DNA Homo sapiens 1 gcacccatgg cagaaggagg agggcagaat catcacgaag tggtgaagtt catggatgtc 60 tatcagcgca gctactgcca tccaatcgag accctggtgg acatcttcca ggagtaccct 120 gatgagatcg agtacatctt caagccatcc tgtgtgcccc tgatgcgatg cgggggctgc 180 tgcaatgacg agggcctgga gtgtgtgccc actgaggagt ccaacatcac catgcagatt 240 atgcggatca aacctcacca aggccagcac ataggagaga tgagcttcct acagcacaac 300 aaatgtgaat gcagaccaaa gaaagataga gcaagacaag aaaatccctg tgggccttgc 360 tcagagcgga gaaagcattt gtttgtacaa gatccgcaga cgtgtaaatg ttcctgcaaa 420 aacacagact cgcgttgcaa ggcgaggcag cttgagttaa acgaacgtac ttgcagatgt 480 gacaagccga ggcgg 495 2 165 PRT Homo sapiens 2 Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys 1 5 10 15 Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu 20 25 30 Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys 35 40 45 Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 50 55 60 Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65 70 75 80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe 85 90 95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg 100 105 110 Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe 115 120 125 Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser 130 135 140 Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys 145 150 155 160 Asp Lys Pro Arg Arg 165 3 2037 DNA Homo sapiens 3 gtccctgata aaactgtgag atggtgtgca gtgtcggagc atgaggccac taagtgccag 60 agtttccgcg accatatgaa aagcgtcatt ccatccgatg gtcccagtgt tgcttgtgtg 120 aagaaagcct cctaccttga ttgcatcagg gccattgcgg caaacgaagc ggatgctgtg 180 acactggatg caggtttggt gtatgatgct tacttggctc ccaataacct gaagcctgtg 240 gtggcagagt tctatgggtc aaaagaggat ccacagactt tctattatgc tgttgctgtg 300 gtgaagaagg atagtggctt ccagatgaac cagcttcgag gcaagaagtc ctgccacacg 360 ggtctaggca ggtccgctgg gtggaacatc cccataggct tactttactg tgacttacct 420 gagccacgta aacctcttga gaaagcagtg gccaatttct tctcgggcag ctgtgcccct 480 tgtgcggatg ggacggactt cccccagctg tgtcaactgt gtccagggtg tggctgctcc 540 acccttaacc aatacttcgg ctactcggga gccttcaagt gtctgaagga tggtgctggg 600 gatgtggcct ttgtcaagca ctcgactata tttgagaact tggcaaacaa ggctgacagg 660 gaccagtatg agctgctttg cctagacaac acccggaagc cggtagatga atacaaggac 720 tgccacttgg cccaggtccc ttctcatacc gtcgtggccc gaagtatggg cggcaaggag 780 gacttgatct gggagcttct caaccaggcc caggaacatt ttggcaaaga caaatcaaaa 840 gaattccaac tattcagctc tcctcatggg aaggacctgc tgtttaagga ctctgcccac 900 gggtttttaa aagtcccccc aaggatggat gccaagatgt acctgggcta tgagtatgtc 960 actgccatcc ggaatctacg ggaaggcaca tgcccagaag ccccaacaga tgaatgcaag 1020 cctgtgaagt ggtgtgcgct gagccaccac gagaggctca agtgtgatga gtggagtgtt 1080 aacagtgtag ggaaaataga gtgtgtatca gcagagacca ccgaagactg catcgccaag 1140 atcatgaatg gagaagctga tgccatgagc ttggatggag ggtttgtcta catagcgggc 1200 aagtgtggtc tggtgcctgt cttggcagaa aactacaata agagcgataa ttgtgaggat 1260 acaccagagg cagggtattt tgctgtagca gtggtgaaga aatcagcttc tgacctcacc 1320 tgggacaatc tgaaaggcaa gaagtcctgc catacggcag ttggcagaac cgctggctgg 1380 aacatcccca tgggcctgct ctacaataag atcaaccact gcagatttga tgaatttttc 1440 agtgaaggtt gtgcccctgg gtctaagaaa gactccagtc tctgtaagct gtgtatgggc 1500 tcaggcctaa acctgtgtga acccaacaac aaagagggat actacggcta cacaggcgct 1560 ttcaggtgtc tggttgagaa gggagatgtg gcctttgtga aacaccagac tgtcccacag 1620 aacactgggg gaaaaaaccc tgatccatgg gctaagaatc tgaatgaaaa agactatgag 1680 ttgctgtgcc ttgatggtac caggaaacct gtggaggagt atgcgaactg ccacctggcc 1740 agagccccga atcacgctgt ggtcacacgg aaagataagg aagcttgcgt ccacaagata 1800 ttacgtcaac agcagcacct atttggaagc aacgtaactg actgctcggg caacttttgt 1860 ttgttccggt cggaaaccaa ggaccttctg ttcagagatg acacagtatg tttggccaaa 1920 cttcatgaca gaaacacata tgaaaaatac ttaggagaag aatatgtcaa ggctgttggt 1980 aacctgagaa aatgctccac ctcatcactc ctggaagcct gcactttccg tagacct 2037 4 679 PRT Homo sapiens 4 Val Pro Asp Lys Thr Val Arg Trp Cys Ala Val Ser Glu His Glu Ala 1 5 10 15 Thr Lys Cys Gln Ser Phe Arg Asp His Met Lys Ser Val Ile Pro Ser 20 25 30 Asp Gly Pro Ser Val Ala Cys Val Lys Lys Ala Ser Tyr Leu Asp Cys 35 40 45 Ile Arg Ala Ile Ala Ala Asn Glu Ala Asp Ala Val Thr Leu Asp Ala 50 55 60 Gly Leu Val Tyr Asp Ala Tyr Leu Ala Pro Asn Asn Leu Lys Pro Val 65 70 75 80 Val Ala Glu Phe Tyr Gly Ser Lys Glu Asp Pro Gln Thr Phe Tyr Tyr 85 90 95 Ala Val Ala Val Val Lys Lys Asp Ser Gly Phe Gln Met Asn Gln Leu 100 105 110 Arg Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser Ala Gly Trp 115 120 125 Asn Ile Pro Ile Gly Leu Leu Tyr Cys Asp Leu Pro Glu Pro Arg Lys 130 135 140 Pro Leu Glu Lys Ala Val Ala Asn Phe Phe Ser Gly Ser Cys Ala Pro 145 150 155 160 Cys Ala Asp Gly Thr Asp Phe Pro Gln Leu Cys Gln Leu Cys Pro Gly 165 170 175 Cys Gly Cys Ser Thr Leu Asn Gln Tyr Phe Gly Tyr Ser Gly Ala Phe 180 185 190 Lys Cys Leu Lys Asp Gly Ala Gly Asp Val Ala Phe Val Lys His Ser 195 200 205 Thr Ile Phe Glu Asn Leu Ala Asn Lys Ala Asp Arg Asp Gln Tyr Glu 210 215 220 Leu Leu Cys Leu Asp Asn Thr Arg Lys Pro Val Asp Glu Tyr Lys Asp 225 230 235 240 Cys His Leu Ala Gln Val Pro Ser His Thr Val Val Ala Arg Ser Met 245 250 255 Gly Gly Lys Glu Asp Leu Ile Trp Glu Leu Leu Asn Gln Ala Gln Glu 260 265 270 His Phe Gly Lys Asp Lys Ser Lys Glu Phe Gln Leu Phe Ser Ser Pro 275 280 285 His Gly Lys Asp Leu Leu Phe Lys Asp Ser Ala His Gly Phe Leu Lys 290 295 300 Val Pro Pro Arg Met Asp Ala Lys Met Tyr Leu Gly Tyr Glu Tyr Val 305 310 315 320 Thr Ala Ile Arg Asn Leu Arg Glu Gly Thr Cys Pro Glu Ala Pro Thr 325 330 335 Asp Glu Cys Lys Pro Val Lys Trp Cys Ala Leu Ser His His Glu Arg 340 345 350 Leu Lys Cys Asp Glu Trp Ser Val Asn Ser Val Gly Lys Ile Glu Cys 355 360 365 Val Ser Ala Glu Thr Thr Glu Asp Cys Ile Ala Lys Ile Met Asn Gly 370 375 380 Glu Ala Asp Ala Met Ser Leu Asp Gly Gly Phe Val Tyr Ile Ala Gly 385 390 395 400 Lys Cys Gly Leu Val Pro Val Leu Ala Glu Asn Tyr Asn Lys Ser Asp 405 410 415 Asn Cys Glu Asp Thr Pro Glu Ala Gly Tyr Phe Ala Val Ala Val Val 420 425 430 Lys Lys Ser Ala Ser Asp Leu Thr Trp Asp Asn Leu Lys Gly Lys Lys 435 440 445 Ser Cys His Thr Ala Val Gly Arg Thr Ala Gly Trp Asn Ile Pro Met 450 455 460 Gly Leu Leu Tyr Asn Lys Ile Asn His Cys Arg Phe Asp Glu Phe Phe 465 470 475 480 Ser Glu Gly Cys Ala Pro Gly Ser Lys Lys Asp Ser Ser Leu Cys Lys 485 490 495 Leu Cys Met Gly Ser Gly Leu Asn Leu Cys Glu Pro Asn Asn Lys Glu 500 505 510 Gly Tyr Tyr Gly Tyr Thr Gly Ala Phe Arg Cys Leu Val Glu Lys Gly 515 520 525 Asp Val Ala Phe Val Lys His Gln Thr Val Pro Gln Asn Thr Gly Gly 530 535 540 Lys Asn Pro Asp Pro Trp Ala Lys Asn Leu Asn Glu Lys Asp Tyr Glu 545 550 555 560 Leu Leu Cys Leu Asp Gly Thr Arg Lys Pro Val Glu Glu Tyr Ala Asn 565 570 575 Cys His Leu Ala Arg Ala Pro Asn His Ala Val Val Thr Arg Lys Asp 580 585 590 Lys Glu Ala Cys Val His Lys Ile Leu Arg Gln Gln Gln His Leu Phe 595 600 605 Gly Ser Asn Val Thr Asp Cys Ser Gly Asn Phe Cys Leu Phe Arg Ser 610 615 620 Glu Thr Lys Asp Leu Leu Phe Arg Asp Asp Thr Val Cys Leu Ala Lys 625 630 635 640 Leu His Asp Arg Asn Thr Tyr Glu Lys Tyr Leu Gly Glu Glu Tyr Val 645 650 655 Lys Ala Val Gly Asn Leu Arg Lys Cys Ser Thr Ser Ser Leu Leu Glu 660 665 670 Ala Cys Thr Phe Arg Arg Pro 675 5 159 DNA Homo sapiens 5 aactctgatt ccgaatgccc gctgtctcat gacggttact gcctgcatga tggcgtatgc 60 atgtacatcg aagctctgga caaatacgca tgcaactgtg ttgtaggtta catcggcgaa 120 cgttgccagt atcgcgacct gaaatggtgg gaactgcgt 159 6 53 PRT Homo sapiens 6 Asn Ser Asp Ser Glu Cys Pro Leu Ser His Asp Gly Tyr Cys Leu His 1 5 10 15 Asp Gly Val Cys Met Tyr Ile Glu Ala Leu Asp Lys Tyr Ala Cys Asn 20 25 30 Cys Val Val Gly Tyr Ile Gly Glu Arg Cys Gln Tyr Arg Asp Leu Lys 35 40 45 Trp Trp Glu Leu Arg 50 7 45 DNA Artificial sequence codes for a polylinker 7 ggtggcggtg gctcgggcgg tggtgggtcg ggtggcggcg gatct 45 8 15 PRT Artificial sequence of a polylinker 8 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 9 1407 DNA Homo sapiens 9 atggctgtcc tggtgctgtt cctctgcctg gttgcatttc caagctgtgt cctgtcccag 60 gtgcacctga aggagtcagg acctggcctg gtggcgccct cacagagcct gtccatcact 120 tgcactgtct ctggattttc attaaccacc tatggtgtac actggtttcg ccagcctcca 180 ggaaagggtc tggagtggct gggactaata tgggctggtg gaaacacaga ttataattcg 240 gctctcatgt ccagactgag catcaacaaa gacaactcca agagccaagt tttcttaaaa 300 atgaacagtc tgcaagctga tgacacagcc atgtactact gtgccagatt tcgctttgct 360 tcttactacg actatgctgt ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 420 tccaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc 480 acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg 540 aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga 600 ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac 660 atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagaaagt tgagcccaaa 720 tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg 780 tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 840 gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 900 gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc 960 acgtaccggg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 1020 tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 1080 gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg 1140 accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 1200 gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg 1260 gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag 1320 caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1380 aagagcctct ccctgtctcc gggtaaa 1407 10 469 PRT Homo sapiens 10 Met Ala Val Leu Val Leu Phe Leu Cys Leu Val Ala Phe Pro Ser Cys 1 5 10 15 Val Leu Ser Gln Val His Leu Lys Glu Ser Gly Pro Gly Leu Val Ala 20 25 30 Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu 35 40 45 Thr Thr Tyr Gly Val His Trp Phe Arg Gln Pro Pro Gly Lys Gly Leu 50 55 60 Glu Trp Leu Gly Leu Ile Trp Ala Gly Gly Asn Thr Asp Tyr Asn Ser 65 70 75 80 Ala Leu Met Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln 85 90 95 Val Phe Leu Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Met Tyr 100 105 110 Tyr Cys Ala Arg Phe Arg Phe Ala Ser Tyr Tyr Asp Tyr Ala Val Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ser Thr Lys Gly 130 135 140 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 145 150 155 160 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 210 215 220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 275 280 285 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 305 310 315 320 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435 440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455 460 Leu Ser Pro Gly Lys 465 11 708 DNA Homo sapiens 11 atggagacag acacactcct gttatgggta ctgctgctct gggttccagg ttccactggt 60 gacattgtgc tgacacagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc 120 atctcatgca gggccagcaa aagtgtcagt acatctggct atagtcatat acactggtac 180 caacagaaac caggacagcc acccaaactc ctcatctatc ttgcatccat cctagaatct 240 ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 300 cctgtggagg aggaggatgc tgcaacctat tactgtcaac acagtaggga atatccgctc 360 acgttcggtg ctgggaccga gctggagctg aaacagccca aggctgcccc ctcggtcact 420 ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 480 agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 540 gcgggagtgg agaccaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 600 tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 660 catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca 708 12 236 PRT Homo sapiens 12 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30 Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser 35 40 45 Val Ser Thr Ser Gly Tyr Ser His Ile His Trp Tyr Gln Gln Lys Pro 50 55 60 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Ile Leu Glu Ser 65 70 75 80 Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 95 Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys 100 105 110 Gln His Ser Arg Glu Tyr Pro Leu Thr Phe Gly Ala Gly Thr Glu Leu 115 120 125 Glu Leu Lys Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 130 135 140 Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 145 150 155 160 Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 165 170 175 Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser 180 185 190 Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln 195 200 205 Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser 210 215 220 Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 225 230 235 

What is claimed is:
 1. A compound comprising at least one ligand and at least one nucleic acid each operatively linked to transferrin wherein said at least one ligand binds complementary receptors where expressed on cell surfaces and said transferrin binds transferrin receptors where expressed on cell surfaces.
 2. A compound in accordance with claim 1 wherein said at least one ligand is vascular endothelial growth factor (VEGF).
 3. A compound in accordance with claim 1 wherein said at least one ligand is epidermal growth factor (EGF).
 4. A pharmaceutical composition comprising the compound of claim 1 and further including a pharmacologically effective amount of a carrier.
 5. A pharmaceutical composition comprising the compound of claim 2 and further including a pharmacologically effective amount of a carrier.
 6. A pharmaceutical composition comprising the compound of claim 3 and further including a pharmacologically effective amount of a carrier.
 7. A conjugate consisting essentially of at least one ligand and at least one nucleic acid each operatively linked to transferrin wherein said at least one ligand binds complementary receptors where expressed on cell surfaces and said transferrin binds transferrin receptors where expressed on cell surfaces.
 8. A conjugate in accordance with claim 7 wherein said at least one ligand is vascular endothelial growth factor (VEGF).
 9. A conjugate in accordance with claim 7 wherein said at least one ligand is epidermal growth factor (EGF).
 10. A pharmaceutical composition comprising the conjugate of claim 7 and further including a pharmacologically effective amount of a carrier.
 11. A pharmaceutical composition comprising the conjugate of claim 8 and further including a pharmacologically effective amount of a carrier.
 12. A pharmaceutical composition comprising the conjugate of claim 9 and further including a pharmacologically effective amount of a carrier.
 13. A compound comprising human vascular endothelial growth factor (VEGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human VEGF binds human VEGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.
 14. A pharmaceutical composition comprising the compound of claim 13 and further including a pharmacologically effective amount of a carrier.
 15. A conjugate consisting essentially of human vascular endothelial growth factor (VEGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human VEGF binds human VEGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.
 16. A pharmaceutical composition comprising the conjugate of claim 15 and further including a pharmacologically effective amount of a carrier.
 17. A compound comprising human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human EGF binds human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.
 18. A pharmaceutical composition comprising the compound of claim 17 and further including a pharmacologically effective amount of a carrier.
 19. A conjugate consisting essentially of human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferrin wherein said human EGF binds human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.
 20. A pharmaceutical composition comprising the conjugate of claim 19 and further including a pharmacologically effective amount of a carrier.
 21. A compound comprising human vascular endothelial growth factor (VEGF), human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferrin, wherein said human VEGF binds to human VEGF receptors where expressed on cell surfaces, said human EGF binds to human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.
 22. A pharmaceutical composition comprising the compound of claim 21 and further including a pharmacologically effective amount of a carrier.
 23. A conjugate consisting essentially of human vascular endothelial growth factor (VEGF), human epidermal growth factor (EGF) and at least one nucleic acid each operatively linked to human transferrin, wherein said human VEGF binds to human VEGF receptors on cell surfaces, said human EGF binds to human EGF receptors where expressed on cell surfaces and said human transferrin binds human transferrin receptors where expressed on cell surfaces.
 24. A pharmaceutical composition comprising the conjugate of claim 23 and further including a pharmacologically effective amount of a carrier.
 25. A compound comprising at least one ligand, SEQ ID NO:9 and SEQ ID NO:11 each operatively linked to transferrin wherein said at least one ligand binds complementary receptors where expressed on cell surfaces and said transferrin binds transferrin receptors where expressed on cell surfaces.
 26. A compound in accordance with claim 25 wherein said at least one ligand is vascular endothelial growth factor (VEGF).
 27. A compound in accordance with claim 25 wherein said at least one ligand is epidermal growth factor (EGF).
 28. A pharmaceutical composition comprising the compound of claim 25 and further including a pharmacologically effective amount of a carrier.
 29. A pharmaceutical composition comprising the compound of claim 26 and further including a pharmacologically effective amount of a carrier.
 30. A pharmaceutical composition comprising the compound of claim 27 and further including a pharmacologically effective amount of a carrier.
 31. A conjugate consisting essentially of at least one ligand, SEQ ID NO: 9 and SEQ ID NO:11 each operatively linked to transferrin wherein said at least one ligand binds complementary receptors where expressed on cell surfaces and said transferrin binds transferrin receptors where expressed on cell surfaces.
 32. A conjugate in accordance with claim 31 wherein said at least one ligand is vascular endothelial growth factor (VEGF).
 33. A conjugate in accordance with claim 31 wherein said at least one ligand is epidermal growth factor (EGF).
 34. A pharmaceutical composition comprising the conjugate of claim 31 and further including a pharmacologically effective amount of a carrier.
 35. A pharmaceutical composition comprising the conjugate of claim 32 and further including a pharmacologically effective amount of a carrier.
 36. A pharmaceutical composition comprising the conjugate of claim 33 and further including a pharmacologically effective amount of a carrier. 